Afatinib and lung cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are crucial in treating non-small-cell lung cancer (NSCLC).
• First-generation reversible EGFR-TKIs are standard for EGFR mutation-positive advanced NSCLC.
• Acquired resistance to reversible EGFR-TKIs necessitates novel therapeutic strategies.

Purpose of the Study:

• To review the preclinical and clinical development of afatinib for NSCLC treatment.
• To highlight afatinib's efficacy in EGFR mutation-positive NSCLC.
• To discuss afatinib's role as a first-line therapy.

Main Methods:

• Preclinical studies assessing afatinib's activity against EGFR, HER2, HER4, and resistant mutants.
• Clinical trials, including the LUX-Lung 3 trial, evaluating afatinib's efficacy and safety.
• Review of regulatory approvals and current treatment guidelines.

Main Results:

• Afatinib demonstrated potent preclinical activity against wild-type and mutant EGFR, HER2, HER4, and resistant NSCLC.
• The LUX-Lung 3 trial showed afatinib's superiority over chemotherapy in treatment-naïve patients with EGFR mutation-positive advanced lung adenocarcinoma.
• Afatinib is approved for first-line treatment of NSCLC patients with EGFR mutations.

Conclusions:

• Afatinib represents a significant advancement in the treatment of EGFR mutation-positive NSCLC.
• Its irreversible binding and broad target profile offer advantages over earlier generations of EGFR-TKIs.
• Afatinib is a validated first-line treatment option for advanced NSCLC with EGFR mutations.